Business and Finance

NEW YORK–Bristol-Myers Squibb Co. says it’s not raising its $60-per-share offer for ImClone Systems Inc., even though the biotechnology company says a secret suitor is offering $10 a share more.

The drugmaker, which has a partnership with ImClone to sell cancer drug Erbitux, also says it won’t agree to any changes in its marketing rights for Erbitux. Bristol-Myers gets a large share of Erbitux’s U.S. sales.

The comments from Bristol-Myers, which owns 17 per cent of ImClone shares, come a day after ImClone said it is considering an offer worth $70 per share from an unidentified large pharmaceutical company online payday advance. That would amount to about $6.1 billion.

ImClone on Wednesday also formally rejected the $4.5 billion July 31 offer from Bristol-Myers.

Source